logo
  

U.K. Approves Rhythm Pharma's Imcivree For Treatment Of Obesity And Control Of Hunger

Rhythm Pharmaceuticals Inc. (RYTM) said that the Great Britain's Medicines & Healthcare Products Regulatory Agency or MHRA has granted marketing authorisation to Imcivree or setmelanotide for the treatment of obesity and the control of hunger associated with genetically confirmed loss-of-function biallelic pro-opiomelanocortin (POMC), including proprotein convertase subtilisin/kexin type 1 or PCSK1, deficiency or biallelic leptin receptor or LEPR deficiency in adults and children 6 years of age and above.

It is the first-ever authorised treatment option in Great Britain (England, Scotland and Wales) for these rare genetic diseases of obesity, the company said.

The National Institute for Health and Care Excellence or NICE is scheduled to review the dossier for Imcivree in December 2021. Guidance for coverage of Imcivree under the United Kingdom's National Health Service (NHS) is anticipated in the second quarter of 2022.

The company noted that the MHRA authorisation of Imcivree is based on results from the largest studies conducted to date in obesity due to POMC, PCSK1 or LEPR deficiency.

In two Phase 3 clinical trials, 8 of 10 patients with obesity due to POMC or PCSK1 deficiency achieved greater than 10 percent body weight loss after one year of treatment with IMCIVREE and 5 of 11 patients with obesity due to LEPR deficiency achieved greater than 10 percent body weight loss after one year of treatment with IMCIVREE.

Additionally, in both studies, significant decreases in body mass index (BMI) were demonstrated across patients who were 6 to 17 years old at baseline.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Apple Inc. may face production shortfall of as many as 6 million iPhone Pro units this year due to ongoing protests at its major China plant, Bloomberg reported citing a person familiar with assembly operations. Following the news, Apple shares were losing around 2.2 percent in pre-market activity on the Nasdaq. Despite fears of inflation, consumers spent $9.12 billion for online shopping during Black Friday, higher than in previous years, as per a report published by Adobe Analytics. During the 2022 holiday season, total estimated revenues are $209.7 billion, a growth of 2.5 percent from last year's recorded revenues of $205 billion. Weis Markets, Inc., a Mid Atlantic food retailer, has recalled 108 containers of Weis Quality Sea Salt Caramel Ripple Ice Cream citing possible presence of undeclared soy and coconut allergens, the U.S. Food and Drug Administration said. The recalled product comes in 48oz containers that says Weis Quality Sea Salt Caramel Ripple Ice Cream, while the lid says Weis Quality Caramel Caribou Ice Cream
RELATED NEWS
Follow RTT